Carmell, N.Rominiyi, O.Myers, K.N.McGarrity-Cottrell, C.Vanderlinden, A.Lad, N.Perroux-David, E.El-Khamisy, SherifFernando, M.Finegan, K.G.Brown, S.Collis, S.J.2023-11-012023-11-102023-11-012023-11-102021-03Carmell N, Rominiyi O, Myers KN et al (2021) Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma. Cancers. 13(5): 944.RMSID:212620505http://hdl.handle.net/10454/19671YesBrain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking surgery combined with chemo-/radiotherapy regimens, the mean survival for these patients is only around 15 months, with less than 10% surviving over 5 years. This dismal prognosis highlights the urgent need to develop novel agents to improve the treatment of these tumours. To address this need, we carried out a human kinome siRNA screen to identify potential drug targets that augment the effectiveness of temozolomide (TMZ)-the standard-of-care chemotherapeutic agent used to treat glioblastoma. From this we identified ERK5/MAPK7, which we subsequently validated using a range of siRNA and small molecule inhibitors within a panel of glioma cells. Mechanistically, we find that ERK5 promotes efficient repair of TMZ-induced DNA lesions to confer cell survival and clonogenic capacity. Finally, using several glioblastoma patient cohorts we provide target validation data for ERK5 as a novel drug target, revealing that heightened ERK5 expression at both the mRNA and protein level is associated with increased tumour grade and poorer patient survival. Collectively, these findings provide a foundation to develop clinically effective ERK5 targeting strategies in glioblastomas and establish much-needed enhancement of the therapeutic repertoire used to treat this currently incurable disease.en(c) 2021 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license ()ERK5MAPK7GlioblastomaTemozolomideDNA damageSensitisationArticlehttps://doi.org/10.3390%2Fcancers13050944CC-BY2023-11-01